ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes.
The cardiotoxic effects of doxorubicin, a potent chemotherapeutic agent, have been linked to DNA damage, oxidative mitochondrial damage, and nuclear translocation of p53, but the exact molecular mechanisms causing p53 transactivation and doxorubicin-induced cardiomyopathy are not clear. The present study was carried out to determine whether extracellular signal-regulated kinases (ERKs), which are known to be activated by DNA damaging agents, are responsible for doxorubicin-induced p53 activation and oxidative mitochondrial damage in H9c2 cells. Cell death was measured by terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling, annexin V-fluorescein isothiocyanate, activation of caspase-9 and -3, and cleavage of poly(ADP-ribose) polymerase (PARP). We found that doxorubicin produced cell death in H9c2 cells in a time-dependent manner, beginning at 6 h, and these changes are associated decreased expression of Bcl-2, increases in Bax and p53 upregulated modulator of apoptosis-alpha expression, and collapse of mitochondria membrane potential. The changes in cell death and Bcl-2 family proteins, however, were preceded by earlier activation and nuclear translocation of ERKs, followed by increased phosphorylation at Ser15 and nuclear translocation of the phosphorylated p53. The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-alpha, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin. U-0126 blocked the phosphorylation and nuclear translocation of both ERK1/2 and p53, whereas PFT-alpha blocked only the changes in p53. Doxorubicin and ERK inhibitors produced similar changes in ERK1/2-p53, PARP, and caspase-3 in neonatal rat cultured cardiomyocytes. Thus we conclude that ERK1/2 are functionally linked to p53 and that the ERK1/2-p53 cascade is the upstream signaling pathway responsible for doxorubicin-induced cardiac cell apoptosis. ERKs and p53 may be considered as novel therapeutic targets for the treatment of doxorubicin-induced cardiotoxicity.
Liu
Jiahao
J
Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Mao
Weike
W
Ding
Bo
B
Liang
Chang-seng
CS
D021581:Active Transport, Cell Nucleus; D000818:Animals; D000831:Animals, Newborn; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects*; D052160:Benzothiazoles / Q000494:pharmacology; D002070:Butadienes / Q000494:pharmacology; D020169:Caspases / Q000378:metabolism; D002478:Cells, Cultured; D004317:Doxorubicin / Q000633:toxicity*; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects*; D013997:Time Factors; D014050:Toluene / Q000031:analogs & derivatives / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; C494828:Bax protein, rat; D052160:Benzothiazoles; D002070:Butadienes; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; C113580:U 0126; D051028:bcl-2-Associated X Protein; D014050:Toluene; D004317:Doxorubicin; C121565:pifithrin; D011065:Poly(ADP-ribose) Polymerases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020169:Caspases
Cancer. 1973 Aug;32(2):302-14
4353012
J Biol Chem. 2000 Dec 15;275(50):39435-43
10993883
Nat Rev Cancer. 2004 Oct;4(10):793-805
15510160
J Biol Chem. 1996 Jul 5;271(27):16047-52
8663242
Cardiovasc Res. 2006 Feb 15;69(3):736-45
16213474
DNA Repair (Amst). 2003 Jan 2;2(1):1-11
12509264
Cell. 2004 Jan 23;116(2):205-19
14744432
Antioxid Redox Signal. 2007 Jul;9(7):1001-8
17508921
Nat Rev Cancer. 2002 Sep;2(9):647-56
12209154
J Biol Chem. 2000 May 5;275(18):13690-8
10788488
Mol Cell Biochem. 2000 Apr;207(1-2):77-86
10888230
Cancer Cell. 2003 Oct;4(4):321-8
14585359
Mol Cancer Ther. 2002 Jul;1(9):679-86
12479364
J Biol Chem. 2000 Nov 17;275(46):35778-85
10958792
Am J Med. 1978 Nov;65(5):823-32
707541
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9
7644477
Endocr Rev. 2001 Apr;22(2):153-83
11294822
Free Radic Biol Med. 2006 Jul 15;41(2):318-25
16814113
J Heart Lung Transplant. 1999 Aug;18(8):744-9
10512520
Curr Opin Immunol. 2007 Oct;19(5):488-96
17629468
J Biol Chem. 2000 Jul 7;275(27):20444-9
10781582
Cancer Res. 1983 Oct;43(10):4543-51
6309369
Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1273-80
16565313
Oncogene. 2006 Jul 6;25(29):4056-66
16491117
Biochem Biophys Res Commun. 2005 Jun 10;331(3):851-8
15865941
J Pharmacol Exp Ther. 2007 Jul;322(1):408-19
17468298
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1925-30
15772336
Cancer Res. 2007 Nov 1;67(21):10428-35
17974986
Mol Cell Biochem. 2005 May;273(1-2):25-32
16013437
Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H933-9
14766674
Drugs. 1997;54 Suppl 4:1-7
9361955
Nature. 2000 Nov 23;408(6811):433-9
11100718
Mol Cell. 2001 Mar;7(3):683-94
11463392
Biochem Biophys Res Commun. 2005 Jun 10;331(3):843-50
15865940
Science. 2004 Jul 30;305(5684):626-9
15286356
J Biol Chem. 2006 Feb 17;281(7):3832-40
16330547
Cell. 1995 Jan 27;80(2):293-9
7834749
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2606-13
16687611
Br J Cancer. 2004 Aug 2;91(3):589-98
15266324
Nat Rev Cancer. 2002 Aug;2(8):594-604
12154352
Cancer. 1976 Feb;37(2 Suppl):1070-8
1253124
J Appl Toxicol. 2005 Sep-Oct;25(5):374-82
16013042
Arch Toxicol. 2006 Mar;80(3):146-53
16180010
Cancer Chemother Pharmacol. 2002 Feb;49(2):133-41
11862427
Toxicol Appl Pharmacol. 2007 Apr 1;220(1):83-91
17292432